EP3164711A4 - Ensemble de biomarqueurs spécifiques pour le diagnostic non invasif d'un cancer du foie - Google Patents
Ensemble de biomarqueurs spécifiques pour le diagnostic non invasif d'un cancer du foie Download PDFInfo
- Publication number
- EP3164711A4 EP3164711A4 EP14896556.9A EP14896556A EP3164711A4 EP 3164711 A4 EP3164711 A4 EP 3164711A4 EP 14896556 A EP14896556 A EP 14896556A EP 3164711 A4 EP3164711 A4 EP 3164711A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- liver cancer
- specific biomarker
- invasive diagnosis
- biomarker set
- invasive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000090 biomarker Substances 0.000 title 1
- 238000003745 diagnosis Methods 0.000 title 1
- 201000007270 liver cancer Diseases 0.000 title 1
- 208000014018 liver neoplasm Diseases 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/321,870 US9885718B2 (en) | 2014-07-02 | 2014-07-02 | Specific biomarker set for non-invasive diagnosis of liver cancer |
US14/321,867 US9506925B2 (en) | 2014-07-02 | 2014-07-02 | Specific biomarker set for non-invasive diagnosis of liver cancer |
PCT/US2014/049038 WO2016003479A1 (fr) | 2014-07-02 | 2014-07-31 | Ensemble de biomarqueurs spécifiques pour le diagnostic non invasif d'un cancer du foie |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3164711A1 EP3164711A1 (fr) | 2017-05-10 |
EP3164711A4 true EP3164711A4 (fr) | 2018-05-23 |
Family
ID=55019816
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP14896556.9A Withdrawn EP3164711A4 (fr) | 2014-07-02 | 2014-07-31 | Ensemble de biomarqueurs spécifiques pour le diagnostic non invasif d'un cancer du foie |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP3164711A4 (fr) |
JP (2) | JP2017520763A (fr) |
KR (1) | KR102086788B1 (fr) |
CN (2) | CN105319362B (fr) |
AU (2) | AU2014399919B2 (fr) |
CA (1) | CA2939912C (fr) |
HK (2) | HK1224370A1 (fr) |
MY (2) | MY179845A (fr) |
NZ (1) | NZ722492A (fr) |
SG (1) | SG11201606106SA (fr) |
TW (1) | TWI700493B (fr) |
UY (1) | UY36200A (fr) |
WO (1) | WO2016003479A1 (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106383231B (zh) * | 2016-09-02 | 2020-03-17 | 四川大学 | 一种诊断肝癌的标记物组合及其应用 |
GB201619954D0 (en) * | 2016-11-25 | 2017-01-11 | Oncimmune Ltd | Antibody assay |
KR102175265B1 (ko) | 2019-03-13 | 2020-11-06 | 충남대학교산학협력단 | Txndc7을 포함하는 간세포암종 진단 또는 예후 예측용 바이오마커 조성물 |
CN110646615B (zh) * | 2019-08-27 | 2021-07-13 | 南方医科大学 | 肝纤维化的生物学标志物、治疗靶点及其用途 |
WO2023282916A1 (fr) | 2021-07-09 | 2023-01-12 | Guardant Health, Inc. | Procédés de détection de réarrangements génomiques à l'aide d'acides nucléiques acellulaires |
EP4179111B1 (fr) | 2020-07-10 | 2024-04-03 | Guardant Health, Inc. | Procédés de détection de réarrangements génomiques à l'aide d'acides nucléiques acellulaires |
CN113502328A (zh) * | 2021-05-27 | 2021-10-15 | 深圳市人民医院 | 检测样本中标志物表达水平的试剂在制备用于检测或诊断乳腺癌的试剂盒中的应用 |
CN113777295B (zh) * | 2021-09-15 | 2024-03-19 | 江南大学 | 用于检测肿瘤标志物pd-l1的高灵敏度量子点探针、制备方法及应用 |
CN113956344A (zh) * | 2021-10-14 | 2022-01-21 | 江南大学 | 一种新型治疗肝癌的fgf类似物及其应用 |
CN114113611B (zh) * | 2021-12-13 | 2023-07-14 | 郑州大学 | 一种用于肝癌诊断的生物标志物及检测试剂盒 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040059519A1 (en) * | 1998-08-18 | 2004-03-25 | Chandler Van S. | Multiplexed analysis of clinical specimens apparatus and methods |
WO2004052392A2 (fr) * | 2002-12-11 | 2004-06-24 | The University Of Birmingham | Immunotherapie anticancereuse |
US20110281284A1 (en) * | 2007-08-10 | 2011-11-17 | Otsuka Pharmaceutical Co., Ltd | Novel liver cancer marker |
WO2013049704A2 (fr) * | 2011-09-28 | 2013-04-04 | Armune Biosciences, Inc. | Procédé et système associés à un complexe particule-épitope de phage |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6893844B1 (en) * | 1998-09-22 | 2005-05-17 | Long Yu | DNA encoding a new human hepatoma derived growth factor and producing method thereof |
US7387881B2 (en) * | 2001-09-19 | 2008-06-17 | The Regents Of The University Of Michigan | Detection and treatment of cancers of the liver |
AU2002361908A1 (en) * | 2001-12-31 | 2003-07-24 | Quark Biotech, Inc. | Methods for identifying marker genes for cancer |
JP3960614B2 (ja) * | 2003-08-31 | 2007-08-15 | 株式会社イムノディア | 抗ペプチド抗体測定法とペプチドワクチンのワクチン候補選択方法 |
GB0406215D0 (en) * | 2004-03-19 | 2004-04-21 | Procure Therapeutics Ltd | Prostate stem cell |
EP1761648A1 (fr) * | 2004-06-18 | 2007-03-14 | Roche Diagnostics GmbH | Utilisation de la proteine pdx1 comme marqueur pour le cancer du sein |
JP5211315B2 (ja) * | 2006-07-25 | 2013-06-12 | 国立大学法人愛媛大学 | 腫瘍マーカ、腫瘍診断キットおよび腫瘍マーカの測定方法 |
US8512963B2 (en) * | 2009-11-25 | 2013-08-20 | The Johns Hopkins University | Detection and quantitation of full-length thioredoxin (TRX) and truncated thioredoxin (TRX 80) in complex samples |
US9523680B2 (en) * | 2010-06-30 | 2016-12-20 | Ambergen, Inc. | Global Proteomic screening of random bead arrays using mass spectrometry imaging |
JP5493130B2 (ja) * | 2010-08-25 | 2014-05-14 | 国立大学法人山口大学 | 自己抗体の検出方法 |
JP2014507160A (ja) * | 2011-02-22 | 2014-03-27 | カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス.アー.エール.エル. | 循環バイオマーカー |
-
2014
- 2014-07-31 AU AU2014399919A patent/AU2014399919B2/en active Active
- 2014-07-31 KR KR1020167032783A patent/KR102086788B1/ko active IP Right Grant
- 2014-07-31 TW TW103126171A patent/TWI700493B/zh active
- 2014-07-31 MY MYPI2017001446A patent/MY179845A/en unknown
- 2014-07-31 JP JP2016571689A patent/JP2017520763A/ja active Pending
- 2014-07-31 SG SG11201606106SA patent/SG11201606106SA/en unknown
- 2014-07-31 NZ NZ72249214A patent/NZ722492A/en unknown
- 2014-07-31 WO PCT/US2014/049038 patent/WO2016003479A1/fr active Application Filing
- 2014-07-31 EP EP14896556.9A patent/EP3164711A4/fr not_active Withdrawn
- 2014-07-31 CA CA2939912A patent/CA2939912C/fr active Active
- 2014-07-31 MY MYPI2016002278A patent/MY195045A/en unknown
-
2015
- 2015-07-01 CN CN201510379493.9A patent/CN105319362B/zh not_active Expired - Fee Related
- 2015-07-01 UY UY0001036200A patent/UY36200A/es unknown
- 2015-07-01 CN CN201710545890.8A patent/CN107478842B/zh active Active
-
2016
- 2016-06-13 HK HK16106781.2A patent/HK1224370A1/zh unknown
- 2016-06-13 HK HK18107745.3A patent/HK1248803A1/zh unknown
-
2017
- 2017-09-21 AU AU2017232129A patent/AU2017232129B2/en not_active Ceased
-
2020
- 2020-06-22 JP JP2020106731A patent/JP2020160082A/ja not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040059519A1 (en) * | 1998-08-18 | 2004-03-25 | Chandler Van S. | Multiplexed analysis of clinical specimens apparatus and methods |
WO2004052392A2 (fr) * | 2002-12-11 | 2004-06-24 | The University Of Birmingham | Immunotherapie anticancereuse |
US20110281284A1 (en) * | 2007-08-10 | 2011-11-17 | Otsuka Pharmaceutical Co., Ltd | Novel liver cancer marker |
WO2013049704A2 (fr) * | 2011-09-28 | 2013-04-04 | Armune Biosciences, Inc. | Procédé et système associés à un complexe particule-épitope de phage |
Non-Patent Citations (2)
Title |
---|
DAI LIPING ET AL: "Using immunomic approach to enhance tumor-associated autoantibody detection in diagnosis of hepatocellular carcinoma", CLINICAL IMMUNOLOGY, vol. 152, no. 1, 22 March 2014 (2014-03-22), pages 127 - 139, XP028638419, ISSN: 1521-6616, DOI: 10.1016/J.CLIM.2014.03.007 * |
KALPA PATEL ET AL: "Enhancement of a multianalyte serum biomarker panel to identify lymph node metastases in non-small cell lung cancer with circulating autoantibody biomarkers", INTERNATIONAL JOURNAL OF CANCER, vol. 129, no. 1, 9 November 2010 (2010-11-09), pages 133 - 142, XP055130158, ISSN: 0020-7136, DOI: 10.1002/ijc.25644 * |
Also Published As
Publication number | Publication date |
---|---|
TWI700493B (zh) | 2020-08-01 |
CN107478842A (zh) | 2017-12-15 |
CN105319362A (zh) | 2016-02-10 |
JP2017520763A (ja) | 2017-07-27 |
JP2020160082A (ja) | 2020-10-01 |
KR102086788B1 (ko) | 2020-03-09 |
CA2939912C (fr) | 2019-04-16 |
UY36200A (es) | 2016-01-29 |
SG11201606106SA (en) | 2016-08-30 |
CN105319362B (zh) | 2018-07-13 |
CA2939912A1 (fr) | 2016-01-07 |
KR20170021234A (ko) | 2017-02-27 |
AU2014399919A1 (en) | 2016-08-11 |
HK1248803A1 (zh) | 2018-10-19 |
TW201602579A (zh) | 2016-01-16 |
WO2016003479A1 (fr) | 2016-01-07 |
HK1224370A1 (zh) | 2017-08-18 |
MY179845A (en) | 2020-11-18 |
AU2014399919B2 (en) | 2019-10-24 |
AU2017232129A1 (en) | 2017-10-12 |
NZ722492A (en) | 2019-09-27 |
EP3164711A1 (fr) | 2017-05-10 |
AU2017232129B2 (en) | 2018-10-25 |
CN107478842B (zh) | 2020-10-16 |
MY195045A (en) | 2023-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3177739A4 (fr) | Biomarqueur à base de microarn utilisable en vue du diagnostic du cancer gastrique | |
EP3209382A4 (fr) | Technique d'immunotherapie combinee pour le traitement du cancer | |
HK1224370A1 (zh) | 用於肝癌的無創診斷的特異性生物標誌物組 | |
EP3268499A4 (fr) | Méthodes de diagnostic de la sepsie | |
EP3307243A4 (fr) | Test de diagnostic pour le cancer à un stade précoce | |
EP3134436A4 (fr) | Traitement de tumeurs provoquées par h-ras | |
EP3232198A4 (fr) | Biomarqueur pour le diagnostic de l'hépatome et son utilisation | |
EP3227686A4 (fr) | Analyses d'immunocytochimie multiplexées pour le diagnostic et le traitement d'un cancer | |
EP3427066A4 (fr) | Biomarqueurs lipidiques destinés au diagnostic du cancer | |
EP3139919A4 (fr) | Composés destinés au traitement du cancer | |
EP3201360A4 (fr) | Procédés pour évaluer le risque de développer un cancer du sein | |
EP3123381A4 (fr) | Compositions et procédés relatifs au diagnostic du cancer de la prostate | |
EP3189333A4 (fr) | Diagnostic du cancer | |
EP3134736A4 (fr) | Utilisation d'interleukine 2 pour le diagnostic de la maladie coeliaque | |
EP3204008A4 (fr) | Utilisation de biomarqueurs permettant de prédire la sensibilité clinique pour le traitement du cancer | |
EP3132802A4 (fr) | Agent thérapeutique pour un cancer solide | |
EP3089992A4 (fr) | Compositions et méthodes pour l'imagerie du cancer | |
EP3298145A4 (fr) | Méthode de diagnostic du cancer du sein | |
EP3426241A4 (fr) | Procédés de diagnostic du cancer | |
EP3152195A4 (fr) | Inhibiteurs mth1 pour le traitement du cancer | |
EP3149209A4 (fr) | Procédés de typage de cancer du poumon | |
EP3139956A4 (fr) | Méthodes d'utilisation d'anticorps anti-ang2 | |
EP3191846A4 (fr) | Procédés pour détecter le cancer de la prostate | |
EP3180011A4 (fr) | Immunothérapie pour le traitement du cancer | |
EP3347051A4 (fr) | Sélection orientée par le séquençage d'une théranostique des tumeurs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20170109 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAX | Request for extension of the european patent (deleted) | ||
RIC1 | Information provided on ipc code assigned before grant |
Ipc: G01N 33/574 20060101AFI20171212BHEP Ipc: G01N 33/564 20060101ALI20171212BHEP |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1237873 Country of ref document: HK |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20180420 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: G01N 33/574 20060101AFI20180416BHEP Ipc: G01N 33/564 20060101ALI20180416BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20190415 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20230726 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1237873 Country of ref document: HK |